Related Experiment Videos
Recalcitrant pyoderma gangrenosum: treatment with thalidomide
1Department of Dermatology, The Mount Sinai Medical Center, New York, New York, USA.
Journal of the American Academy of Dermatology
|March 31, 1998
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.
Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis.
Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study.
Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial.
Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.
Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Clinical outcomes associated with a digital standardized skin care regimen in acne-rosacea comorbidity: A real-world longitudinal study with cross-lagged and mediation analyses.
Journal of the American Academy of Dermatology·2026
Real-world outcomes of 24-week abrocitinib tapering in moderate-to-severe atopic dermatitis: Feasibility and regimen comparison.
Journal of the American Academy of Dermatology·2026
Dabrafenib-Induced Cutaneous Eruptions in a Patient With Langerhans Cell Histiocytosis.
Case reports in dermatological medicine·2026
Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis.
Frontiers in endocrinology·2026
Lipocalin-2 Emerges as a Core Pathogenic Mediator and Biomarker in Autosomal Dominant Tubulointerstitial Kidney Disease-UMOD via Transcriptomic Profiling.
Kidney diseases (Basel, Switzerland)·2026
Targeting TKT-associated immunometabolic remodeling attenuates experimental lupus nephritis and NET-related inflammation.
Frontiers in cell and developmental biology·2026